OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer
Cassie Liu, Carter J. Barger, Adam R. Karpf
Cancers (2021) Vol. 13, Iss. 12, pp. 3065-3065
Open Access | Times Cited: 72
Cassie Liu, Carter J. Barger, Adam R. Karpf
Cancers (2021) Vol. 13, Iss. 12, pp. 3065-3065
Open Access | Times Cited: 72
Showing 1-25 of 72 citing articles:
FOXM1: A small fox that makes more tracks for cancer progression and metastasis
Md Arafat Khan, Parvez Κhan, Aatiya Ahmad, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 1-15
Open Access | Times Cited: 57
Md Arafat Khan, Parvez Κhan, Aatiya Ahmad, et al.
Seminars in Cancer Biology (2023) Vol. 92, pp. 1-15
Open Access | Times Cited: 57
Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer
Benita S. Katzenellenbogen, Valeria Sanabria Guillen, John A. Katzenellenbogen
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 38
Benita S. Katzenellenbogen, Valeria Sanabria Guillen, John A. Katzenellenbogen
Breast Cancer Research (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 38
Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy
Weijia Wang, Wenjun Liu, Qiuli Chen, et al.
Seminars in Cancer Biology (2022) Vol. 87, pp. 84-97
Closed Access | Times Cited: 28
Weijia Wang, Wenjun Liu, Qiuli Chen, et al.
Seminars in Cancer Biology (2022) Vol. 87, pp. 84-97
Closed Access | Times Cited: 28
PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities
Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 155019-155019
Closed Access | Times Cited: 20
Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan, et al.
Pathology - Research and Practice (2023) Vol. 253, pp. 155019-155019
Closed Access | Times Cited: 20
The role of the STAT3 signaling transduction pathways in radioresistance
Po‐Chang Shih
Pharmacology & Therapeutics (2022) Vol. 234, pp. 108118-108118
Closed Access | Times Cited: 23
Po‐Chang Shih
Pharmacology & Therapeutics (2022) Vol. 234, pp. 108118-108118
Closed Access | Times Cited: 23
Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics
Peyman Tabnak, Aysa Hasanzade Bashkandi, Mohammad Ebrahimnezhad, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Peyman Tabnak, Aysa Hasanzade Bashkandi, Mohammad Ebrahimnezhad, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 15
A patient-derived organoid-based study identified an ASO targeting SNORD14E for endometrial cancer through reducing aberrant FOXM1 Expression and β-catenin nuclear accumulation
Xi Chen, Xin Liu, Qian-hui Li, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 13
Xi Chen, Xin Liu, Qian-hui Li, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 13
Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments
Sanjeev Raghuwanshi, Andrei L. Gartel
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189015-189015
Closed Access | Times Cited: 13
Sanjeev Raghuwanshi, Andrei L. Gartel
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 189015-189015
Closed Access | Times Cited: 13
Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies
Sanjeev Raghuwanshi, Xu Zhang, Zarema Arbieva, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
Sanjeev Raghuwanshi, Xu Zhang, Zarema Arbieva, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 5
A computational and structural approach to identify malignant non-synonymous FOXM1 single nucleotide polymorphisms in triple-negative breast cancer
Prarthana Chatterjee, Satarupa Banerjee
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Prarthana Chatterjee, Satarupa Banerjee
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
FOXM1 Participates in Scleral Remodeling in Myopia by Upregulating APOA1 Expression Through METTL3/YTHDF2
Min Xue, Boai Li, Yao Lu, et al.
Investigative Ophthalmology & Visual Science (2024) Vol. 65, Iss. 1, pp. 19-19
Open Access | Times Cited: 4
Min Xue, Boai Li, Yao Lu, et al.
Investigative Ophthalmology & Visual Science (2024) Vol. 65, Iss. 1, pp. 19-19
Open Access | Times Cited: 4
NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells
Cassie Liu, Makenzie Vorderbruggen, Catalina Muñoz-Trujillo, et al.
Journal of Ovarian Research (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Cassie Liu, Makenzie Vorderbruggen, Catalina Muñoz-Trujillo, et al.
Journal of Ovarian Research (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Disruption of the FOXM1 Regulatory Region Inhibits Tumor Progression in Ovarian Cancer by CRISPR‐Cas9
Yujie Chen, Yingzhuo Xue, Qiuwen Jiang, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
Yujie Chen, Yingzhuo Xue, Qiuwen Jiang, et al.
Drug Development Research (2025) Vol. 86, Iss. 1
Closed Access
FOXM1, a super enhancer-associated gene, is related to poorer prognosis and gemcitabine resistance in pancreatic cancer
Jian Jiang, Tong Shen, Dan Chen, et al.
Cell Biochemistry and Biophysics (2025)
Closed Access
Jian Jiang, Tong Shen, Dan Chen, et al.
Cell Biochemistry and Biophysics (2025)
Closed Access
The Potential of Pharmacological Intervention Targeting NEDD4 in Glioma
Amjad Z. Alrosan, Enaam Al Momany, Ghaith B. Heilat, et al.
Heliyon (2025), pp. e42996-e42996
Open Access
Amjad Z. Alrosan, Enaam Al Momany, Ghaith B. Heilat, et al.
Heliyon (2025), pp. e42996-e42996
Open Access
Deciphering FOXM1 regulation: implications for stemness and metabolic adaptations in glioblastoma
Kumari Swati, Saniya Arfin, Kirti Agrawal, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access
Kumari Swati, Saniya Arfin, Kirti Agrawal, et al.
Medical Oncology (2025) Vol. 42, Iss. 4
Closed Access
Investigation of the mechanism by which FOXJ2 inhibits proliferation, metastasis and cell cycle progression of ovarian cancer cells through the PI3K/AKT signaling pathway
Liyuan Wang, Han He, Ruifang Zhai, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Liyuan Wang, Han He, Ruifang Zhai, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
Genes as Genome Stabilizers in Pluripotent Stem Cells
A Karmakar, Allan Blessing Harison Raj Augustine, Rajkumar P. Thummer
Advances in experimental medicine and biology (2025)
Closed Access
A Karmakar, Allan Blessing Harison Raj Augustine, Rajkumar P. Thummer
Advances in experimental medicine and biology (2025)
Closed Access
Bioinformatics study and cytotoxicity of several curcumin analogues in ovarian cancer
Retno Murwanti, Ritmaleni Ritmaleni, Navista Sri Octa Ujiantari, et al.
Current Research in Toxicology (2025), pp. 100230-100230
Open Access
Retno Murwanti, Ritmaleni Ritmaleni, Navista Sri Octa Ujiantari, et al.
Current Research in Toxicology (2025), pp. 100230-100230
Open Access
The acidic microenvironment promotes pancreatic cancer progression via the lncRNA-LOC100507424/E2F1/FOXM1 axis
Di Mu, Ying Shi, Runxuan Sun, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Di Mu, Ying Shi, Runxuan Sun, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
New mechanism of miR-34a-5p in regulating the biological behavior of osteosarcoma by targeting FoxM1
Wenxiang Shen, Xiang Liu, Shengdong Wang, et al.
Cytotechnology (2025) Vol. 77, Iss. 3
Closed Access
Wenxiang Shen, Xiang Liu, Shengdong Wang, et al.
Cytotechnology (2025) Vol. 77, Iss. 3
Closed Access
Molecular Management of High-Grade Serous Ovarian Carcinoma
Paula Punzón-Jiménez, Víctor Lago, Santiago Domingo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13777-13777
Open Access | Times Cited: 18
Paula Punzón-Jiménez, Víctor Lago, Santiago Domingo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13777-13777
Open Access | Times Cited: 18
Estrogen Receptor-Beta2 (ERβ2)–Mutant p53–FOXM1 Axis: A Novel Driver of Proliferation, Chemoresistance, and Disease Progression in High Grade Serous Ovarian Cancer (HGSOC)
Chetan C. Oturkar, Nishant Gandhi, Pramod Rao, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1120-1120
Open Access | Times Cited: 16
Chetan C. Oturkar, Nishant Gandhi, Pramod Rao, et al.
Cancers (2022) Vol. 14, Iss. 5, pp. 1120-1120
Open Access | Times Cited: 16
Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness
Chiara Battistini, Hilary A. Kenny, Melissa Zambuto, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 3
Chiara Battistini, Hilary A. Kenny, Melissa Zambuto, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 5
Open Access | Times Cited: 3
Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs
Valeria Sanabria Guillen, Yvonne Ziegler, Chirag Gopinath, et al.
Breast Cancer Research and Treatment (2023) Vol. 198, Iss. 3, pp. 607-621
Closed Access | Times Cited: 8
Valeria Sanabria Guillen, Yvonne Ziegler, Chirag Gopinath, et al.
Breast Cancer Research and Treatment (2023) Vol. 198, Iss. 3, pp. 607-621
Closed Access | Times Cited: 8
